CommunityDispatch.com
U.S.Government News and Current Events

Contact Us | Submit News |About Us| Subscribe | Home Page


Home Page Here for More Exciting News

Search








 


Clinical Trial Studies
RSS Feed RSS Feed
Last Updated: Jul 21, 2011 - 12:58:55 PM

Treating Alcohol Withdrawal Clinical Trial Opportunity


By Clinical Trials


Jan 25, 2008 - 8:07:40 AM


Treating Alcohol Withdrawal Clinical Trial Opportunity

 

Purpose

The purpose of this study is determine if subjects with alcohol withdrawal who receive oral baclofen, plus standard benzodiazepine therapy, will experience less severe withdrawal symptoms than those who receive placebo plus standard benzodiazepine therapy.Subjects with alcohol withdrawal syndrome(AWS)who receive baclofen plus standard benzodiazepine therapy will experience fewer complications of AWS (as measured by use of additional sedatives, restraints, and/or ICU admissions) compared with subjects who receive placebo plus standard benzodiazepine therapy.

Detailed Description:

Alcohol use is ubiquitous in American society. 83% of americans have ever consumed alcohol, 51% have in the lst month.

The average american consumes 2.18 gallons of ethanol yearly. Alcohol related morbidity and mortality are staggering problems in the USA. Symptoms of alcohol withdrawal occur because alcohol is a central nervous system depressant; abrupt withdrawal unmasks compensatory overactivity of certain parts of the nervous system, including sympathetic autonomic outflow. 5% of patients who undergo alcohol suffer from Delirium Tremors (DTs), a syndrome characterized by hallucinations, disorientation, tachycardia, hypertension, low grade fever, agitation, and diaphoresis.

DTs typically begin between 48-96 hours after the last drink and last 1 to 5 days. DTs requires hospitalization and vigorous activity in an ICU setting.

The most sucessful drug treatment for alcohol withdrawal has been found to be the benzodiazepines.

Symptom triggered treatment was found to be as effective as a fixed dose treatment to result in less drug being used overall, with a trend toward shorter duration of withdrawal treatment.

Baclofen is used orally for the treatment of spasticity resulting from multiple sclerosis, spinal cord injuries/diseases and intrathecally for spasticity related to cerebral palsy, spinal cord injury, and ALS.

Its proposed benefit in alcohol withdrawal is that it may reduce voluntary alcohol intake, alcohol craving, and may suppress the intensity of alcohol withdrawal treatment.

For More information

Alcohol Withdrawal Clinical Trial

Other Related Information

  • Treatment
  • Prevention/Screening
  • [an error occurred while processing this directive]



    Clinical Trial Studies
    Latest Headlines


    Recruiting Patients: Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy
    Women's Depression Treatment Study Recruiting Participants
    Women-Focused HIV Prevention in the Western Cape, recruiting participants.
    Prevention of Relapse to Cocaine Use: Recruiting Participants
    Prostate Cancer Trial: Pomegranate Juice in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery
    Fostering Mothers' Emotionally Responsive Parenting, Recruiting Participants
    Metabolic Study of Sleep Apnea in Men and Women, Recruiting Participants
    Prostate-Specific Antigen Screening in African American Men, Recruiting Participants

    alcohol, alcohol abuse, alcohol treatment, alcohol rehab, effects of alcohol, alcohol withdrawal , alcohol addiction, alcohol effects